Skip to main
TXG
TXG logo

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 35%
Sell 0%
Strong Sell 6%

Bulls say

The financial outlook for 10x Genomics Inc appears positive, driven by projected improvements in production efficiency and increasing throughput, particularly with the Media Luna project expected to enhance quarterly results through 2025. The company's innovative product lines, especially the Xenium and Visium HD platforms, are anticipated to generate robust market demand, contributing significantly to revenue growth. Despite a recent reorganization impacting customer engagement in the Americas, the strong adoption of new offerings suggests potential for improved gross margins in the long term.

Bears say

10x Genomics Inc faces a negative outlook primarily due to the heightened competition that could lead to a loss of market share if competitors successfully develop superior offerings. The company is also encountering challenges such as a tight funding environment affecting research budgets, which may hinder its near- and long-term growth potential, evidenced by a year-over-year revenue decline of approximately 1%, missing estimates. Additionally, the launch of the Visium HD product is critical, as any failure or complications in its rollout could lead to further adverse reactions in the stock's performance.

10X Genomics (TXG) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 35% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 17 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.97, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.97, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.